NZ585661A - Phenylpyrazole derivatives - Google Patents

Phenylpyrazole derivatives

Info

Publication number
NZ585661A
NZ585661A NZ585661A NZ58566108A NZ585661A NZ 585661 A NZ585661 A NZ 585661A NZ 585661 A NZ585661 A NZ 585661A NZ 58566108 A NZ58566108 A NZ 58566108A NZ 585661 A NZ585661 A NZ 585661A
Authority
NZ
New Zealand
Prior art keywords
alkyl
phenyl
alkoxy
halogen
methylpyrrolidin
Prior art date
Application number
NZ585661A
Other languages
English (en)
Inventor
Toshio Nakamura
Makoto Tatsuzuki
Dai Nozawa
Tomoko Tamita
Seiji Masuda
Hiroshi Ohta
Shuhei Kashiwa
Aya Fujino
Shigeyuki Chaki
Toshiharu Shimazaki
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of NZ585661A publication Critical patent/NZ585661A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ585661A 2007-11-13 2008-11-13 Phenylpyrazole derivatives NZ585661A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007294040 2007-11-13
JP2008153736 2008-06-12
PCT/JP2008/070712 WO2009063953A1 (ja) 2007-11-13 2008-11-13 フェニルピラゾール誘導体

Publications (1)

Publication Number Publication Date
NZ585661A true NZ585661A (en) 2012-04-27

Family

ID=40638800

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ585661A NZ585661A (en) 2007-11-13 2008-11-13 Phenylpyrazole derivatives

Country Status (24)

Country Link
US (3) US7888354B2 (enExample)
EP (1) EP2221298B1 (enExample)
JP (2) JP4543344B2 (enExample)
KR (1) KR101571176B1 (enExample)
CN (1) CN101855211B (enExample)
AU (1) AU2008321823B2 (enExample)
BR (1) BRPI0820432B8 (enExample)
CA (1) CA2705502C (enExample)
CY (1) CY1114877T1 (enExample)
DK (1) DK2221298T3 (enExample)
ES (1) ES2436146T3 (enExample)
HR (1) HRP20131060T1 (enExample)
IL (2) IL205509A (enExample)
MX (1) MX2010005225A (enExample)
MY (1) MY173546A (enExample)
NZ (1) NZ585661A (enExample)
PH (1) PH12012501917A1 (enExample)
PL (1) PL2221298T3 (enExample)
PT (1) PT2221298E (enExample)
RS (1) RS53125B (enExample)
RU (1) RU2480456C2 (enExample)
SI (1) SI2221298T1 (enExample)
WO (1) WO2009063953A1 (enExample)
ZA (1) ZA201003111B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113776A1 (en) * 2006-12-14 2010-05-06 Taisho Pharmaceutical Co.,Ltd. Pyrazole derivative
CN101855211B (zh) * 2007-11-13 2013-06-12 大正制药株式会社 苯基吡唑衍生物
JP5740838B2 (ja) * 2009-05-12 2015-07-01 大正製薬株式会社 フェニルピラゾール誘導体
BR112014013461A2 (pt) * 2011-12-08 2017-06-13 Taisho Pharmaceutical Co Ltd derivado de fenilpirrol
US20150045553A1 (en) * 2011-12-27 2015-02-12 Taisho Pharmaceutical Co., Ltd Phenyltriazole derivative
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2928474B1 (en) 2012-12-07 2018-11-14 ChemoCentryx, Inc. Diazole lactams
JP6263553B2 (ja) * 2013-01-17 2018-01-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ疾患の処置のためのオキシトシン受容体アゴニスト
SG11201808626WA (en) 2016-04-07 2018-10-30 Chemocentryx Inc Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
ATE354568T1 (de) 2000-08-08 2007-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden
US6316475B1 (en) * 2000-11-17 2001-11-13 Abbott Laboratories Aminoalkoxybiphenylcarboxamides as histamine-3 receptor ligands and their therapeutic applications
EP1370546A2 (en) * 2001-03-16 2003-12-17 Abbott Laboratories Novel amines as histamine-3 receptor ligands and their therapeutic applications
AU2004257025B9 (en) 2003-06-27 2010-05-27 Msd K.K. Heteroaryloxy nitrogenous saturated heterocyclic derivative
US7423147B2 (en) 2004-03-31 2008-09-09 Janssen Pharmaceutical, N.V. Pyridine compounds as histamine H3 modulators
GB0408083D0 (en) 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
CN101006082B (zh) 2004-08-23 2010-09-29 伊莱利利公司 组胺h3受体药剂、制备方法和治疗用途
MX2007004465A (es) 2004-10-19 2007-05-07 Hoffmann La Roche Derivados de quinolina.
WO2006046131A1 (en) 2004-10-29 2006-05-04 Pfizer Products Inc. Tetralin histamine-3 receptor antagonists
CA2588867A1 (en) 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. Substituted pyridone derivative
US20090306052A1 (en) 2004-12-07 2009-12-10 Glaxo Group Limited Indenyl derivatives and use thereof for the treatment of neurological disorders
CA2602336A1 (en) * 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
AU2006232871B9 (en) 2005-04-01 2011-11-24 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
DE102005033448A1 (de) * 2005-07-18 2007-01-25 Josef Gail Druckgas-Zylinderläufermotor
GB0514812D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0514811D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
ATE525072T1 (de) 2006-02-09 2011-10-15 Athersys Inc Pyrazole zur behandlung von adipositas und anderen zns-erkrankungen
US20100113776A1 (en) 2006-12-14 2010-05-06 Taisho Pharmaceutical Co.,Ltd. Pyrazole derivative
CN101711232A (zh) * 2007-04-12 2010-05-19 Dsm精细化学奥地利Nfg两合公司 邻-氯甲基苯基乙醛酸酯、(e)-2-(2-氯甲基苯基)-2-烷氧亚胺基乙酸酯的改进制备方法以及用于这些制备方法的新型中间体
CN101855211B (zh) * 2007-11-13 2013-06-12 大正制药株式会社 苯基吡唑衍生物

Also Published As

Publication number Publication date
ZA201003111B (en) 2011-08-31
RU2480456C2 (ru) 2013-04-27
CA2705502C (en) 2016-01-26
US20100267687A1 (en) 2010-10-21
EP2221298A1 (en) 2010-08-25
AU2008321823A1 (en) 2009-05-22
EP2221298B1 (en) 2013-11-06
ES2436146T3 (es) 2013-12-27
IL205509A (en) 2015-09-24
MX2010005225A (es) 2010-05-27
PL2221298T3 (pl) 2014-05-30
CN101855211B (zh) 2013-06-12
SI2221298T1 (sl) 2013-12-31
IL236083A (en) 2016-12-29
WO2009063953A1 (ja) 2009-05-22
DK2221298T3 (da) 2013-11-18
RU2010123924A (ru) 2011-12-20
US20110065668A1 (en) 2011-03-17
AU2008321823B2 (en) 2013-03-07
CN101855211A (zh) 2010-10-06
US20110065667A1 (en) 2011-03-17
JPWO2009063953A1 (ja) 2011-03-31
KR101571176B1 (ko) 2015-11-23
JP4543344B2 (ja) 2010-09-15
BRPI0820432B8 (pt) 2021-05-25
EP2221298A4 (en) 2011-09-21
MY173546A (en) 2020-02-04
CA2705502A1 (en) 2009-05-22
BRPI0820432B1 (pt) 2020-01-14
US7888354B2 (en) 2011-02-15
JP5375639B2 (ja) 2013-12-25
US8183387B2 (en) 2012-05-22
HK1145834A1 (en) 2011-05-06
PH12012501917A1 (en) 2014-10-17
BRPI0820432A2 (pt) 2015-05-26
US8193176B2 (en) 2012-06-05
RS53125B (sr) 2014-06-30
HRP20131060T1 (hr) 2013-12-20
IL236083A0 (en) 2015-01-29
IL205509A0 (en) 2010-12-30
CY1114877T1 (el) 2016-12-14
KR20100083795A (ko) 2010-07-22
PT2221298E (pt) 2013-12-03
JP2010143943A (ja) 2010-07-01

Similar Documents

Publication Publication Date Title
NZ585661A (en) Phenylpyrazole derivatives
IL294504A (en) Converted pyrazolo-pyrimidines and their uses
CN101395139B (zh) 西格玛受体化合物
AU2012349290B2 (en) Phenylpyrrole derivative
US20100113776A1 (en) Pyrazole derivative
EP3116504A2 (en) Retinoic acid receptor-related orphan receptor modulators and uses thereof
JP5740838B2 (ja) フェニルピラゾール誘導体
JP2010090067A (ja) 含窒素複素環誘導体
HK1145834B (en) Phenylpyrazole derivatives
JP2015027999A (ja) フェニルトリアゾール誘導体を含有する医薬
NZ626089B2 (en) Phenylpyrrole derivative
JP2015013853A (ja) フェニルピロール誘導体を含有する医薬

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2016 BY DENNEMEYER + CO.

Effective date: 20151023

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2017 BY DENNEMEYER + CO.

Effective date: 20161020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2018 BY DENNEMEYER + CO

Effective date: 20171025

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2019 BY DENNEMEYER + CO

Effective date: 20181020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2020 BY DENNEMEYER + CO

Effective date: 20191022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2021 BY PETRA OLK

Effective date: 20201102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2022 BY DENNEMEYER + CO.

Effective date: 20211030

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2023 BY DENNEMEYER + CO.

Effective date: 20221101

LAPS Patent lapsed